NEWS
Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock
Windtree Therapeutics (NasdaqCM: WINT) announced positive topline results from its Phase 2b SEISMiC Extension Study of istaroxime in early cardiogenic shock.
The study met its primary endpoint, significantly improving systolic blood pressure over six hours compared to placebo.
Significant benefits were also observed in many secondary endpoints.
The study evaluated two different dose regimens of istaroxime against placebo, with infusions lasting up to 60 hours. It focused on improving low blood pressure and heart function in SCAI Stage B cardiogenic shock patients. The safety profile was favorable and consistent with previous clinical trials.
Detailed results will be presented at the Heart Failure Society of America Meeting on September 30, 2024. Windtree plans to issue a press release with more detailed results and conduct an investor call following the presentation.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1633Followers
89Following
12KVisitors
Follow